Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

21. Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Enzalutamid (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 August 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A20-46 Enzalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A20-46 Version 1.0 Enzalutamide (prostate cancer) 12 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Enzalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

22. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) .2020.09.046. Online ahead of print. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK. Electronic address: Philip.Cornford@liverpoolft.nhs.uk. 2 Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands. 3 Hasselt, Belgium. 4 Department of Urology

2020 EvidenceUpdates

23. Darolutamide (Nubeqa) - non-metastatic castration resistant prostate cancer (nmCRPC)

Darolutamide (Nubeqa) - non-metastatic castration resistant prostate cancer (nmCRPC) 1 Published 09 November 2020 1 SMC2297 darolutamide 300mg film-coated tablets (Nubeqa®) Bayer plc 9 October 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full (...) submission darolutamide (Nubeqa®) is accepted for use within NHSScotland. Indication under review: Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. In a phase III study in men with high risk nmCRPC, treatment with darolutamide was superior to placebo for metastasis-free survival. High risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2

2020 Scottish Medicines Consortium

24. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. Full Text available with Trip Pro

Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. To assess treatment related changes in quality of life up to 15 years after diagnosis of localised prostate cancer.Population based, prospective cohort study with follow-up over 15 years.New South Wales, Australia.1642 men with localised prostate cancer, aged less than 70, and 786 controls randomly recruited from the New South Wales electoral roll into the New South Wales (...) Prostate Cancer Care and Outcomes Study (PCOS).General health and disease specific quality of life were self-reported at seven time points over a 15 year period, using the 12-item Short Form Health Survey scale, University of California, Los Angeles prostate cancer index, and expanded prostate cancer index composite short form (EPIC-26). Adjusted mean differences were calculated with controls as the comparison group. Clinical significance of adjusted mean differences was assessed by the minimally

2020 BMJ

25. Apalutamide and Overall Survival in Prostate Cancer Full Text available with Trip Pro

Apalutamide and Overall Survival in Prostate Cancer Apalutamide and Overall Survival in Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature (...) Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Eur Urol Actions . 2020 Sep 6;S0302-2838(20)30628-X. doi: 10.1016/j.eururo.2020.08.011. Online ahead of print. Apalutamide and Overall Survival in Prostate Cancer , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Massachusetts

2020 EvidenceUpdates

26. Therapies for Clinically Localized Prostate Cancer

Therapies for Clinically Localized Prostate Cancer Therapies for Clinically Localized Prostate Cancer Comparative Effectiveness Review Number 230 R Comparative Effectiveness Review Number 230 Therapies for Clinically Localized Prostate Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN (...) on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report. AHRQ appreciates appropriate acknowledgment and citation of its work. Suggested language for acknowledgment: This work was based on an evidence report, Therapies for Clinically Localized Prostate Cancer, by the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ). Suggested citation: Dahm P, Brasure M, Ester E, Linskens EJ, MacDonald R, Nelson VA, Ryan

2020 Effective Health Care Program (AHRQ)

27. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. (Abstract)

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy (...) approaches.We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (age ≥18 years) with intermediate-risk or high-risk, localised or locally advanced prostate cancer. We searched trial registers and conference proceedings until July 8, 2020, to identify eligible RCTs. By establishing

2020 Lancet

28. Factors predicting outcome with multi-rsistant advanced prostate cancer treated with prostate specific membrane antigen radioligand therapy. A systematic review and meta-analysis Full Text available with Trip Pro

Factors predicting outcome with multi-rsistant advanced prostate cancer treated with prostate specific membrane antigen radioligand therapy. A systematic review and meta-analysis Factors predicting outcome with multi-rsistant advanced prostate cancer treated with prostate specific membrane antigen radioligand therapy. A systematic review and meta-analysis | Morressier We use cookies to ensure that we give you the best experience on our website Got it Signup Login Home Saved research Copy DOI (...) Download Submission Factors predicting outcome with multi-rsistant advanced prostate cancer treated with prostate specific membrane antigen radioligand therapy. A systematic review and meta-analysis Submitted Sep 23, 2020 12 Views 0 Downloads 0 Saves Video PDF Abstract 2 Datasets Video Presented at Oct 10 - 14, 2020 Presentation Download Abstract The aim was to evaluate whether characteristics for patient s with metastatic multiresistant prostate cancer and treatment with PSMA radioligand therapy (PRLT

2020 Morressier

29. Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Full Text available with Trip Pro

Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis | Research Square Browse Tools & Services Your Cart See (...) / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Lei Peng, Jinze Li, Chuanyang Meng, Jinming Li, Chengyu You, Dandan Tang, Tangqiang Wei, Wei Xiong, Yunxiang Li Lei Peng North Sichuan Medical University Jinze Li North Sichuan Medical University Chuanyang Meng North Sichuan Medical University Jinming Li Affiliated Hospital of North Sichuan Medical College Chengyu You North Sichuan Medical University Dandan Tang

2020 Research Square

30. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (Abstract)

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final (...) ) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 0.29 to 1.06) in the overall population.Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide

2020 NEJM

31. Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints (...) . The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis Anze Yu, Kai Xie, Changsheng Xing, Qilin Qin, Longfei Liu, Xiongbing Zu Anze Yu Xiangya Hospital Central South University ORCiD: https://orcid.org/0000-0002-3998-1198 Kai Xie

2020 Research Square

32. The Application of Artificial Intelligence in Prostate Cancer Management—What Improvements Can Be Expected? A Systematic Review Full Text available with Trip Pro

The Application of Artificial Intelligence in Prostate Cancer Management—What Improvements Can Be Expected? A Systematic Review Applied Sciences | Free Full-Text | The Application of Artificial Intelligence in Prostate Cancer Management—What Improvements Can Be Expected? A Systematic Review Next Article in Journal Previous Article in Journal Previous Article in Special Issue Information Initiatives Notice You can make submissions to other journals . You seem to have javascript disabled. Please (...) products and services. Information Our dedicated information section provides allows you to learn more about MDPI. JSmol Viewer Open Access Review The Application of Artificial Intelligence in Prostate Cancer Management—What Improvements Can Be Expected? A Systematic Review by 1,2,* , 2 , 3 , 2 , 2 , 2 , 2 , 2 , 4,5,6,7,8,9,10 , 4,11,* and 1,2 1 IRSET, 35000 Rennes, France 2 Department of Urology, Service d’urologie, Rennes University Hospital, Hôpital Pontchaillou, 2, rue Henri Le Guilloux, 35000

2020 Applied Sciences

33. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. (Abstract)

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time (...) . The incidence of adverse events after the start of treatment was similar in the two groups; no new safety signals were observed.Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of patients who were alive at 3 years was significantly higher among those who received darolutamide than among those who received placebo. The incidence of adverse events was similar in the two groups. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614

2020 NEJM

34. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) ):3042-3050. doi: 10.1200/JCO.20.00315. Epub 2020 Jul 24. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Memorial Sloan Kettering Cancer Center, New York, NY. 2 Department of Biostatistics and Bioinformatics, Duke University, Durham, NC. 3 The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital

2020 EvidenceUpdates

35. Prostate Cancer Part 1: Diagnosis and Referral in Primary Care

Prostate Cancer Part 1: Diagnosis and Referral in Primary Care Prostate Cancer Part 1: Diagnosis and Referral in Primary Care - Province of British Columbia B.C. has declared a state of emergency. Learn about . | . theme_13_collection theme_13_frontend theme_13_collection theme_13_frontend Employment, business and economic development theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, adoption, death, marriage and divorce theme_data_collection data_frontend (...) Public safety and emergency services theme_10_collection theme_10_frontend theme_10_collection theme_10_frontend Sports, recreation, arts and culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes and tax credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism and immigration Search default_collection default_frontend Section Navigation Prostate Cancer Part 1: Diagnosis and Referral in Primary Care Effective Date: April 15, 2020

2020 Clinical Practice Guidelines and Protocols in British Columbia

36. Prostate Cancer Part 2: Follow-up in Primary Care

Prostate Cancer Part 2: Follow-up in Primary Care Prostate Cancer Part 2: Follow-up in Primary Care - Province of British Columbia B.C. has declared a state of emergency. Learn about . | . theme_13_collection theme_13_frontend theme_13_collection theme_13_frontend Employment, business and economic development theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, adoption, death, marriage and divorce theme_data_collection data_frontend theme_data_collection data_frontend (...) and emergency services theme_10_collection theme_10_frontend theme_10_collection theme_10_frontend Sports, recreation, arts and culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes and tax credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism and immigration Search default_collection default_frontend Section Navigation Prostate Cancer Part 2: Follow-up in Primary Care Effective Date: April 15, 2020 Recommendations and Topics Scope

2020 Clinical Practice Guidelines and Protocols in British Columbia

37. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis Full Text available with Trip Pro

Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis Cite as Li H, Fei X, Shen Y, Wu Z. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis. Adv Clin Exp Med. 2020;29(8):1001–1009. doi:10.17219/acem/121521 DOI 10.17219/acem/121521 Copyright © 2020 by Wroclaw Medical University This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) (https://creativecommons.org/licenses/by/3.0/) Address (...) on September 1, 2020 Abstract Previous studies have suggested that prostate-specific antigen (PSA) plays a role in the etiology of prostate cancer (PCa), and that polymorphisms of KLK3 may be associated with PCa. However, these results were con?icting. Therefore, we performed a meta-analysis to illuminate this problem. We searched the PubMed and Web of Science databases. Ten single nucleotide polymorphisms (SNPs) were involved in this meta-analysis. The pooled results showed that the minor alleles

2020 Advances in Clinical and Experimental Medicine

38. Diagnostic ability of DCE-MRI for prostate cancer and clinically significant prostate cancer in equivocal lesions: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Diagnostic ability of DCE-MRI for prostate cancer and clinically significant prostate cancer in equivocal lesions: A Systematic Review and Meta-analysis Inplasy Protocol 730 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

39. A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation using External Beam or Stereotactic Radiotherapy: Systematic Review and Meta-Analysis Full Text available with Trip Pro

A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation using External Beam or Stereotactic Radiotherapy: Systematic Review and Meta-Analysis Redirecting

2020 Advances in radiation oncology

40. Association of rs3746444 in MiRNA-499 and rs3787016 in Long Non-coding RNAs POLR2E with Prostate Cancer: an updated meta-analysis and systematic review Full Text available with Trip Pro

Association of rs3746444 in MiRNA-499 and rs3787016 in Long Non-coding RNAs POLR2E with Prostate Cancer: an updated meta-analysis and systematic review Association of rs3746444 in MiRNA-499 and rs3787016 in Long Non-coding RNAs POLR2E with Prostate Cancer: an updated meta-analysis and systematic review | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct (...) peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Association of rs3746444 in MiRNA-499 and rs3787016 in Long Non-coding RNAs POLR2E with Prostate Cancer: an updated meta-analysis and systematic review Xuebin Liu, Yan Liu, Zhaozhang Wang, Yuwu Li, Yubin Li, Zihao Zou, Jianfeng Zhong, Nan Deng, Gaorui Zhou

2020 Research Square